金花股份最新一期业绩显示，截至2025一季报，公司营业总收入1.07亿元、同比减少7.31%，归属净利 润121.53万元，同比减少94.93%，扣非净利润1067.46万元，同比增长151.79%，流动比率1.939、速动比 率1.850、资产负债率21.65%。 金融界消息 截至2025年8月12日收盘，金花股份（600080）报收于7.77元，下跌1.15%，换手率1.7%， 成交量6.33万手，成交金额4928.16万元。 资金流向方面，今日主力资金净流入1254.95万元，占比成交额25.46%。其中，超大单净流入267.21万 元、占成交额5.42%，大单净流入987.74万元、占成交额20.04%，中单净流出流出1164.57万元、占成交 额23.63%，小单净流出90.38万元、占成交额1.83%。 天眼查商业履历信息显示，金花企业(集团)股份有限公司，成立于1996年，位于西安市，是一家以从事 医药制造业为主的企业。企业注册资本37327.0285万人民币，实缴资本8245万人民币。公司法定代表人 为邢雅江。 通过天眼查大数据分析，金花企业(集团)股份有限公司共对外投资了21家企业，参与招投 ...

证券代码：600080 股票简称：金花股份 编号：临 2025-033 金花企业（集团）股份有限公司 关于公司进行融资租赁的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 主要内容：金花企业（集团）股份有限公司 （以下简称"公司"）拟 以公司自有医药生产制造设备为租赁标的，与陕西高科融资租赁有限责任公司 （以下简称"高科融资租赁"）开展融资租赁售后回租业务，融资总额 1000 万元， 主要用于设备采购，融资期限 24 个月。 公司董事长、法定代表人邢雅江先生、副总经理邢博越先生为本次融资租赁 事项提供连带责任保证担保。本次担保公司不需支付任何担保费用，也未向其提 供反担保，符合公司和全体股东的利益，不会对公司生产经营造成不利影响。根 据《上海证券交易所股票上市规则》之相关规定，上市公司单方面获得利益且不 支付对价、不附任何义务的交易，包括受赠现金资产、获得债务减免、无偿接受 担保和财务资助等，可以免于按照关联交易的方式审议和披露，因此本次由关联 方提供的担保不再按照关联交易方式审议及披露。 高科融资 ...

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the A-share listed companies, 1,144 secretaries earned over 1 million yuan annually, accounting for over 21% [1] - The age distribution of secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] Group 2 - The educational background of secretaries indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] - Only three secretaries hold a doctoral degree, specifically from Yiling Pharmaceutical, Kunming Pharmaceutical Group, and Jinhua Co., Ltd. [3] Group 3 - The average annual salary of secretaries in A-share listed Chinese medicine companies is 742,400 yuan, with 39% earning below 500,000 yuan, 42% earning between 500,000 and 1 million yuan, and 15% earning between 1 million and 2 million yuan [5] - The top five highest-paid secretaries are from China Resources Sanjiu, Jichuan Pharmaceutical, Tianjin Pharmaceutical, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries ranging from 1.3935 million to 2.5587 million yuan [7] Group 4 - There is significant variation in the number of investor receptions among listed companies, with 59% receiving fewer than 10 times a year, while 3% received between 300 and 1,000 times [9] - The five companies with the highest number of investor receptions are Zoli Pharmaceutical, Qizheng Pharmaceutical, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with receptions ranging from 207 to 410 times [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (27 individuals, 39%), between 500,000-1,000,000 yuan (29 individuals, 42%), between 1,000,000-2,000,000 yuan (10 individuals, 15%), between 2,000,000-3,000,000 yuan (2 individuals, 3%), and above 3,000,000 yuan (1 individual, 1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earners and Investor Relations - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu (2.5587 million yuan) - Cao Wei from Jichuan Pharmaceutical (2.4107 million yuan) - Yu Jie from Tian Shi Li (2.525 million yuan) - Wu Rui from Yiling Pharmaceutical (1.89 million yuan) - Jiang Xianhong from Yibai Pharmaceutical (1.3935 million yuan) [7] - The frequency of investor meetings varies significantly among companies, with 41 companies hosting fewer than 10 meetings annually (59%), 17 companies holding 10-100 meetings (25%), 9 companies conducting 100-300 meetings (13%), and 2 companies having 300-1000 meetings (3%) [7] Most Active Companies in Investor Relations - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical (410 meetings) - Qizheng Tibetan Medicine (404 meetings) - Yunnan Baiyao (298 meetings) - Jinghua Pharmaceutical (221 meetings) - Pian Zai Huang (207 meetings) [9]

Core Insights - The report highlights that the total salary for A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earn over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries is as follows: - Below 500,000 yuan: 27 individuals (39%) - 500,000-1,000,000 yuan: 29 individuals (42%) - 1,000,000-2,000,000 yuan: 10 individuals (15%) - 2,000,000-3,000,000 yuan: 2 individuals (3%) - Above 3,000,000 yuan: 1 individual (1%) [5] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 42%, while those over 50 account for 29%, and those under 40 make up 26% [1] - The educational background indicates that 5% have an associate degree, 42% hold a bachelor's degree, 49% possess a master's degree, and 4% have a doctoral degree, with over half of the secretaries holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are: - Xing Jian from China Resources Sanjiu: 2.5587 million yuan - Cao Wei from Jichuan Pharmaceutical: 2.4107 million yuan - Yu Jie from Tianjin Tasly: 2.525 million yuan - Wu Rui from Yiling Pharmaceutical: 1.89 million yuan - Jiang Xianhong from Yibai Pharmaceutical: 1.3935 million yuan - Their tenure at the companies ranges from less than 1 year to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies: - Less than 10 meetings: 41 companies (59%) - 10-100 meetings: 17 companies (25%) - 100-300 meetings: 9 companies (13%) - 300-1000 meetings: 2 companies (3%) [7] - The five companies with the highest number of investor meetings are: - Zoli Pharmaceutical: 410 meetings - Qizheng Pharmaceutical: 404 meetings - Yunnan Baiyao: 298 meetings - Jinghua Pharmaceutical: 221 meetings - Pianzihuang: 207 meetings [9]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - The data indicates that over 21% of company secretaries earn more than 1 million yuan annually [1] Salary Distribution - The average annual salary for company secretaries in the A-share traditional Chinese medicine sector is 742,400 yuan [5] - The distribution of salaries shows that 39% earn below 500,000 yuan, 42% earn between 500,000 and 1 million yuan, 15% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age and Educational Background - The age distribution of company secretaries shows that 42% are between 40-50 years old, 29% are over 50, and 26% are under 40 [1] - In terms of educational qualifications, 5% have an associate degree, 42% hold a bachelor's degree, 49% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Top Earning Company Secretaries - The top five highest-paid company secretaries are from Huaren Sanjiu, Jichuan Pharmaceutical, Tianshili, Yiling Pharmaceutical, and Yibai Pharmaceutical, with salaries of 2.5587 million yuan, 2.4107 million yuan, 2.525 million yuan, 1.89 million yuan, and 1.3935 million yuan respectively [7] - The tenure of these top earners varies, with some having less than one year of service and others having up to 15 years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 59% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the most investor meetings are Zoli Pharmaceutical, Qizheng Tibetan Medicine, Yunnan Baiyao, Jinghua Pharmaceutical, and Pianzihuang, with 410, 404, 298, 221, and 207 meetings respectively [9]

Group 1 - The company held its 20th meeting of the 10th Board of Directors on July 10, 2025, via remote voting, with all 7 participating directors voting [1][2] - The board approved the appointment of Mr. Zhang Chaoyang as the Secretary of the Board, effective immediately until the end of the current board's term [1][2] - The board also approved the adjustment of the Audit Committee, electing Mr. Xing Yajiang as a member, while the other members remain unchanged [2]

证券代码：600080 证券简称：金花股份 公告编号：临 2025-031 金花企业（集团）股份有限公司 关于调整董事会审计委员会委员及聘任董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会审计委员会委员辞职及调整董事会审计委员会委员的情况 金花企业（集团）股份有限公司（以下简称"公司"）董事会于近日收到 公司董事张朝阳先生递交的书面辞职报告，张朝阳先生因个人工作调整原因辞 去第十届董事会审计委员会委员职务，辞职后，张朝阳先生将继续担任公司董 事。该辞职报告自送达公司董事会之日起生效。 根据《公司法》、《上海证券交易所股票上市规则》、《上市公司章程指 引》等相关规定，为进一步完善公司治理结构，保障公司规范运作，董事会选 举邢雅江先生为公司第十届董事会审计委员会委员，任期自公司董事会审议通 过之日起至第十届董事会任期届满之日止。除上述调整外，公司第十届董事会 审计委员会委员保持不变。 调整前后公司第十届董事会审计委员会委员情况如下： 调整前：吴雅婕、刘晓娟、张朝阳 上述事项已经公司 2025 年 ...

金花企业（集团）股份有限公司 证券代码：600080 股票简称：金花股份 编号：临 2025-032 （二）通过《关于调整董事会审计委员会委员的议案》 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 第十届董事会第二十次会议决议公告 根据《公司法》、《上海证券交易所股票上市规则》、《上市公司章程指引》等 相关规定，张朝阳先生辞去担任的公司审计委员会委员职务。为进一步完善公司 治理结构，保障公司规范运作，董事会选举邢雅江先生为公司第十届董事会审计 委员会委员，任期自公司董事会审议通过之日起至第十届董事会任期届满之日 止。除上述调整外，公司第十届董事会审计委员会委员保持不变。调整后，公司 第十届董事会审计委员会成员为：吴雅婕、刘晓娟、邢雅江。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 金花企业（集团）股份有限公司（以下简称"公司"）第十届董事会第二十 次会议通知于 2025 年 7 月 9 日以电子邮件及微信方式发出，会议于 2025 年 7 月 10 日以通讯表决方式召开。应参与表决 ...

Core Viewpoint - The company has received a case acceptance receipt from the public security authority regarding a lawsuit against its former actual controller and controlling shareholder for misappropriating company funds [2][3]. Group 1: Legal Proceedings - The company is currently in the litigation stage after receiving the case acceptance receipt from the public security authority [2]. - The company has been involved in multiple lawsuits initiated by small investors, totaling 590 cases with a cumulative compensation amount of 43.982 million yuan [3]. - The company is actively pursuing legal actions against its former controlling shareholder, Jin Hua Investment Holding Group Co., Ltd., and its former actual controller, Wu Yijian, to protect the rights of the company and its shareholders [3][4]. Group 2: Financial Impact - The misappropriation of funds amounts to 16.772 million yuan, which was allegedly facilitated through contracts with third parties and related parties [3]. - The company has reported that its business operations remain normal despite the ongoing legal issues, although the impact of the case on the company is uncertain [4]. Group 3: Information Disclosure - The company commits to timely information disclosure regarding the progress of the case and will cooperate with the economic crime investigation team [4]. - The designated media for information disclosure includes the Shanghai Securities Journal and the Shanghai Stock Exchange website [4].